A prospective trial evaluating topographical distribution of tau pathology and its effect on functional and structural changes in healthy controls and patients with Alzheimer disease and mild cognitive impairment (MCI) by using 18F-AV-1451 PET.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flortaucipir-F-18 (Primary) ; Florbenazine F18
Indications Alzheimer's disease; Mild cognitive impairment
Focus Diagnostic use

Most Recent Events

14 Jul 2016 New trial record
29 Jun 2016 Results published in the Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight